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Penzel et al.1 recently described a lung adenocarcinoma patient with 
an EML4-ALK fusion between exon 
6 of echinoderm microtubule associ-
ated protein like 4 (EML4) and exon 19 
of anaplastic lymphoma kinase (ALK) 
(E6;A19) as a novel molecular variant. 
It should be noted that this EML4-ALK 
(E6;A19) fusion has been previously 
reported by our group in a 62-year-old 
woman also with lung adenocarcinoma.2 
The second finding of this atypical 
EML4-ALK breakpoint (the majority of 
ALK gene fusions occur at exon 20 of 
ALK) suggests that it may not be an iso-
lated event, and highlights the great diver-
sity of fusion events involving this gene. 
Furthermore, an FN1-ALK gene fusion 
was previously identified in a malignant 
stromal sarcoma patient, in which the 
fusion also occurs at exon 19 of ALK.3 
The significance of these ALK exon 19 
fusion variants is currently unknown, 
but is interesting as it expresses the ALK 
transmembrane domain. The subcellular 
localization of these exon 19-containing 
variants should be further investigated to 
better understand the implications of this 
finding; prior evidence suggests EML4-
ALK (E13;A20) is localized within the 
cytoplasm.4 Oncogenic fusions involv-
ing ROS1 and RET in lung cancer have 
been shown previously to also include 
the transmembrane domain in some 
instances.5 The patient described by our 
group demonstrated a partial response 
to crizotinib and experienced a pro-
gression free survival of approximately 
6.5-months, supporting the argument 
that these patients be considered for ALK 
inhibitor therapy like other patients who 
are positive for ALK rearrangements.2
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In Response:
We thank Le et al.1 for their comment 
on our recent article on a rare variant of 
an EML4-ALK fusion between exon 6 of 
EML4 and exon 19 of ALK. Indeed, the 
same mutation was reported by Doebele 
et al.2 shortly before our article was 
published; this was not evident to us at 
the time we prepared and submitted our 
article. The increasing detection of rare 
EML4-ALK fusions corroborates the 
great diversity of ALK translocations 
in lung cancer and raises the need to 
further investigate the tumorbiological 
significance of these rare events and the 
patients’ responses to ALK inhibitors. 
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The reported partial response to 
Crizotinib2 provides first evidence that 
patients with exon 19-containing vari-
ants of EML4-ALK might also benefit 
from ALK inhibitors.
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A Phase I Study of 
Concurrent External 
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Topotecan  
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Lung Cancers
To the Editor:
The optimal treatment of patients 
with locally advanced lung cancer 
remains to be defined. Combined modal-
ity treatment, usually with concomitant 
chemotherapy and radiation therapy, 
is administered usually as definitive 
therapy for patients who are poor sur-
gical candidates. Currently, available 
Roland Penzel, PhD 
Peter Schirmacher, Prof 
Arne Warth, MD
Institute für Pathology
University Hospital Heidelberg
Heidelberg, Germany
Disclosure: Robert C. Doebele and Marileila 
Varella-Garcia have received Speaker fees for 
internal preceptorship from Pfizer. Dr. Doebele 
has also received research grant from Pfizer. 
The authors declare no conflicts of interest.
Address for correspondence: Robert C. Doebele, 
MD, PhD, Department of Medicine, Division 
of Medical Oncology, University of Colorado 
Anschutz Medical Campus, Aurora, CO. 
E-mail: robert.doebele@ucdenver.edu
Disclosure: The authors declare no conflicts of 
interest.
Address for correspondence: Dennie Jones, 
MD, Division of Hematology and Oncology, 
Department of Internal Medicine, University 
of New Mexico Cancer Center, 900 Camino 
de Salud MSC 08 4360, Albuquerque, NM 
87131-0001. E-mail: dvjones@salud.unm.edu
Copyright © 2012 by the International Association 
for the Study of Lung Cancer
ISSN: 1556-0864/12/0712- e44
Doi: 10.1097/JTO.0b013e3181cf32c8
